Caliber Associates Recruits Chief Medical Officer for Atreca Inc.

January 30, 2023 – San Diego, CA- based Caliber Associates recently placed Philippe Bishop as the chief medical officer of Atreca Inc. in San Carlos, CA. “Dr. Bishop’s leadership and expertise in developing oncology therapeutics will contribute significantly to Atreca’s executive team,” said Steve Hochberg, CEO of Caliber Associates.

“Dr. Bishop is a tremendous addition to the Atreca team at an important time in the clinical development of ATRC-101,” said John Orwin, CEO of Atreca. “As an accomplished executive and medical oncologist with extensive experience in cancer drug development, his leadership and expertise will be invaluable as we continue to advance ATRC-101, as well as our earlier stage programs. I am pleased to welcome him to Atreca and look forward to his contributions as we prepare to commence indication-specific development of ATRC-101. We plan to present new data from the ongoing Phase 1b study later this quarter, including an update on our clinical strategy.”

Dr. Bishop joins Atreca from Clover Biopharmaceuticals, a global biotech company focused on the development of vaccines and biologics, where he served as chief medical officer. Previously, he was EVP and chief medical officer at, a developer of novel cancer immunotherapies. Before founding in 2017, Dr. Bishop was senior vice president hematology / oncology at Gilead Sciences and held clinical development roles at Genentech, Johnson & Johnson and Sanofi-Aventis. Prior to his industry career, he held leadership positions at the U.S. Food and Drug Administration and National Institutes of Health.

Dr. Bishop received his medical degree from the University of Nevada School of Medicine followed by a residency in internal medicine at the University of Washington School of Medicine and a medical oncology fellowship at the National Cancer Institute.

“I believe that ATRC-101 has generated compelling data in the ongoing clinical study, validating the ability of Atreca’s discovery platform to identify active tumor targeting antibodies,” said Dr. Bishop. “I’m excited to join a highly talented and dedicated team as we continue to develop ATRC-101 and begin to advance additional novel antibodies into the clinic.”

Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors.

Last year, Caliber Associates placed Stephen Gould as chief scientific officer of Atreca. Dr. Gould joined Atreca following 15 years at Genentech, where he held positions of increasing responsibility, most recently serving as executive director, translational oncology. At Genentech, he led a team focused on developing tumor specific antibodies weaponized with immune-targeting arms or drug payloads for use in both hematologic and solid tumors, including two approved medicines.

Prior to joining Genentech, Dr. Gould served as senior director, oncology at Curis. Dr. Gould received his doctorate from the University of Connecticut Health Center in development biology and held postdoctoral fellowships at the University of California, San Francisco in the department of orthopedic surgery, and the University of Virginia in the department of biology.

Related: Caliber Associates Recruits Chief Medical Officer for GentiBio

“Stephen is an exceptional scientific leader with particular experience in the development of weaponized antibody-based therapeutics, and we are excited to welcome him to the Atreca team,” said John Orwin, CEO of Atreca. “Our discovery platform has proven to be highly productive in generating promising tumor-selective lead antibodies against novel targets and target epitopes, and Stephen’s expertise will be invaluable as we continue to build and advance our preclinical pipeline.”

Recruiting for the Life Sciences

Caliber Associates, founded in 1988, is focused exclusively on the life sciences sector. The firm has partnered with over 200 leading companies and has completed upwards of 750 searches, placing strategic leaders with broad therapeutic and functional reach. The firm has offices in San Diego, Atlanta, and Philadelphia.

Leadership in a Post-Covid World
In this brand new episode of “Talent Talks,” Hunt Scanlon Media host Rob Adams is joined by Steve Hochberg, CEO of Caliber Associates. In this podcast, Mr. Hochberg discusses how COVID-19 has changed leadership expectations and then shares how leaders can promote and sustain culture as employees return to the workplace. Listen now!

Among the roles Caliber Associates has recently filled include senior vice president, clinical development at Inovio Pharmaceuticals and chief medical officer of Coherus BioSciences.

Mr. Hochberg focuses on recruiting CEOs, board members, C-level, and strategic teams for emerging life science companies and global biopharmaceutical companies. He has assembled a small team of highly experienced, results driven search professionals. Prior to his search career, Mr. Hochberg held strategic human resources roles with Rhône-Poulenc Rorer, FMC Corp., and Shell Oil Co.

Related: Caliber Associates Fills Senior Post for Sutro Biopharma

Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Managing Editor; and Stephen Sawicki, Managing Editor – Hunt Scanlon Media

Share This Article


Notify of
Inline Feedbacks
View all comments